Skip to main content
Premium Trial:

Request an Annual Quote

Health Discovery Inks Second Biomarker, Pathway Deal with MD Anderson Cancer Center

NEW YORK, Jan. 26 (GenomeWeb News) - Health Discovery said today that it has signed an agreement acquiring the first option to obtain the exclusive worldwide rights to commercialize prostate cancer biomarkers or pathways identified by the company as part of a collaboration with the University of Texas, MD Anderson Cancer Center.

 

The option for the royalty-bearing commercialization license was granted by the MD Anderson, said Health Discovery. Additional terms of the deal, which the comapny said is its second with the cancer center, were not disclosed.

 

 

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.